Molecular biomarkers of Alzheimer's disease: progress and prospects

Disease Models & Mechanisms

Jonathan M. Schott¹  Philip Weston¹  Ashvini Keshavan¹  Jonathan D. Rohrer¹  Henrik Zetterberg²  Martha Foiani²  Amanda Heslegrave²  Jamie Toombs²  Henny Wellington²  Tammaryn Lashley³  Christina E. Murray³  Sandrine C. Foti³ 

[1] Dementia Research Centre, UCL Institute of Neurology, London WC1N 3BG, UK;Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK;Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK;

关键词: Alzheimer's disease;    Biomarkers;    Cerebrospinal fluid;    Blood;    Plasma;    Serum;    Tau;    Amyloid;    Neurofilament;    Neurogranin;   

DOI  :  10.1242/dmm.031781

来源: DOAJ

【 摘 要 】

The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse and neuronal loss. This leads to clinical symptoms, such as progressive memory deficits. Clinically, these pathological changes can be detected in the cerebrospinal fluid and with brain imaging, although reliable blood tests for plaque and tangle pathologies remain to be developed. Plaques and tangles often co-exist with other brain pathologies, including aggregates of transactive response DNA-binding protein 43 and Lewy bodies, but the extent to which these contribute to the severity of Alzheimer's disease is currently unknown. In this ‘At a glance’ article and poster, we summarise the molecular biomarkers that are being developed to detect Alzheimer's disease and its related pathologies. We also highlight the biomarkers that are currently in clinical use and include a critical appraisal of the challenges associated with applying these biomarkers for diagnostic and prognostic purposes of Alzheimer's disease and related neurodegenerative disorders, also in their prodromal clinical phases.

【 授权许可】

Unknown